Replies to post #29265 on Radient Pharmaceuticals Corporation fka RXPC

[runncoach]

Yeah I can laugh about since I haven't owned any in years. Feel sorry for those trapped with a total loss but the SEC at least gave a few weeks before it was revoked so they can really only blame themselves. We know the rest of the story now and this is there is no rest of the story IMO.

[GetSeriousOK]

Here is what I believe.

-> RXPC stock will never trade again.

-> Radient Pharmaceuticals will never be an active corporation in the USA again.

What else matters?

Who cares what Provista or GCDx does (or doesn't do)? Nothing they do or plan to do has any effect on RXPC shares or Radient Pharmaceuticals. In the remote chance that Provista ever does anything with DR-70, it will be off patent and therefore will not benefit RXPC ex-shareholders in any way.

Who cares what UNI does (or doesn't do)? Their Radient Agreement terminated last year.

And since the discussion keeps drifting to GCDX for some reason, here is what I believe about GCDx.

-> The test being marketed (notice I did not say "sold" because I doubt they are selling much if any) is just the same old failed DR-70 that was marketed by Radient Pharmaceuticals from 1995-2014 and is now off patent.

-> GCDx will never turn a profit from selling this test because DR-70 has no support from the Medical Community or Government and there is ZERO chance that DR-70 will ever be cleared by the FDA as a cancer screener. Radient couldn't get it cleared for anything other than MONITORING CRC and only then when used in conjunction with CEA.

-> GCDx is getting their specificity / sensitivity numbers from Radient's old studies and trials. They won't make their white paper or trial/study results available -- I believe this is because they never did their own trials or studies.

-> Since DR-70 is off patent, if there was money to be made, someone with funding (like JnJ or GSK) would market DR-70 and crush GCDx. The fact that nobody else in the US wants to market DR-70 says it all.

[GetSeriousOK]

The merger rumor died when shares were revoked.

The merger rumor was almost plausible in 2011 if Jade was worth $20 million, NuVax was a valid spinoff possibility, and India annual revenues were going to be $10 - $12 million in 2011.

Unfortunately, we learned in 2012 that Jade was worth nothing, NuVax evaporated and was worthless, and India Revenues turned out to be zero.

As a result, the merger rumor became implausible in 2012. However, buyout rumors that can't be absolutely proven false always have a tiny thread of life in the world of zombie biotechs.

Unfortunately, RXPC changed from being a zombie biotech to being nothing when the company declared itself insolvent, share registration was revoked, the directors and officers quit and appointed new Directors and Officers from a different continent, and the new Directors and Officers removed all means of communication and disappeared.

[bAs a result, the merger rumor is dead. It's not "mostly dead," it is DEAD.

[guardiangel]

Radient Restructured By A Planned Reverse Merger


We have concluded from the planned merger between Radient and Provista Diagnostics according to the LOI of 2010 and our completed analysis that Provista Diagnostics will either merge with Radient or reverse triangular merge Global Cancer Diagnostics with Radient.
The agreement between AMDL Diagnostics and Uni-Pharma and the agreement between Radient and Global Cancer Diagnostics were set up on a temporary basis and conveniently terminated after the last patent expired. Radient and Provista Diagnostics still have an exclusive 5 year agreement in force and Radient and Uni-Pharma are also in an exclusive and existing five year agreement. Those two agreements superseded the two previously terminated agreements. The Lung Cancer Test a/k/a LC Sentinel is still owned by Radient and Provista Diagnostics and included in their 5 year exclusive and collaborated agreement from November 2010 to research, develop, and commercialize cancer tests including the Lung Cancer Test. William Gartner sold his lung cancer and breast cancer to Provista Diagnostics in 2011.
The 4.5 billion RXPC shares outstanding are held by Institutional investors who had converted their debt for equity, and Angel investors who we believe are associated with Provista Diagnostics. After the announcement of revocation and insolvency, RXPC shares were accumulated and not sold. During the 2012 to July 3, 2014 period of trading,the creeping take over groups quietly took all the shares that Radient released slowly and in a timely manner to the public. If "ebabies" retailers etc that some are calling them were buying,they would have been the first to sell shares. As you can see from the lack of interest on this board before 2012 and after 2013...Enjoy our deductive logic approach to our premisses....

"Radient Is Being Restructured By A Planned Reverse Merger."

If:Radient wants and needs to be restructured by a merger and not by bankruptcy.

Then:Provista Diagnostics wants to go public

Therefore:Provista Diagnostics will merge according to the planned merger LOI of 2010 and the planned restructuring of Radient


*Uni-Pharma-Radient Dx Current Agreements and Past Agreement

http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2457187542.html

http://contractservices.pharmaceutical-business-review.com/news/radient-expands-distribution-agreement-with-unipharma-221211

http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm


*Radient Dx and Provista-Global Cancer Dx Current Agreements

http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_ex10-1.htm

*Radient Dx and Provista DX /Global Cancer DX Lung Cancer Test

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

http://www.bizjournals.com/phoenix/print-edition/2011/12/30/provista-to-go-public-with-breast.html

http://www.biocentury.com/products/lc_sentinel


*Over 38 Million Dollars Lender Debt Converted to Stock

http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-1.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_ex10-2.htm

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112765409

http://seekingalpha.com/instablog/424698-m-e-garza/177461-regarding-latest-8k-filing-by-radient-pharmaceuticals-rpc

*All Accounts Payable Paid in Full By GCDx and Uni-Pharma Royalties/ License Agreements,Onko-Sure Sales in India,Taiwan,Korea,etc.and Attorney Debt to Equity Agreement

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112733314

*SRL Limited and Metropolis Healthcare Currently Selling Onko-Sure/Cancer 8 Throughout India

http://www.west-info.eu/it/analisi-del-sangue-13-tipi-tumore-cancro/2012-02-onkosure-fibrin-fdp-in-cancer-mm-2/

http://www.metropolisindia.com/patients/cancer-eight


*Institutional Shareholders

http://www.prnewswire.com/news-releases/radient-pharmaceuticals-corporation-completes-restructurings-with-institutional-investors-to-limit-conversions-and-stock-sales-and-provide-for-potential-additional-capital-134659763.html

http://www.sec.gov/Archives/edgar/data/838879/000121390012000035/0001213900-12-000035-index.htm

http://www.sec.gov/Archives/edgar/data/838879/000121390012002920/sc13g052112whale_radient.htm

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7538329

http://msnmoney.brand.edgar-online.com/DisplayFilingInfo.aspx?TabIndex=2&FilingID=7717117&type=html&companyid=4985&ppu=%2fDefault.aspx%3fticker%3drpc

http://www.sec.gov/Archives/edgar/data/838879/000136456011000007/stgeo_sc13g.htm

http://www.sec.gov/Archives/edgar/data/838879/000101968711002819/bristol_13ga-082411.htm

http://www.sec.gov/Archives/edgar/data/838879/000121390011003768/sc13g0711a1whale_radient.htm

http://www.sec.gov/Archives/edgar/data/838879/000121390011003763/sc13g0711a1alpha_radient.htm

http://www.sec.gov/Archives/edgar/data/838879/000090266411001142/p11-1347sc13g.htm

http://www.sec.gov/Archives/edgar/data/838879/000101968712000550/bristolradient_13ga2.htm

http://www.sec.gov/Archives/edgar/data/838879/000119312512059770/d301526dsc13ga.htm

http://www.sec.gov/Archives/edgar/data/838879/000090266412000289/p12-0319sc13ga.htm

Conclusion:

http://provistadx.com/

http://globalcancerdx.com/

http://azbio.tv/video/76134461f30e472d8f08be36f73bc095

http://seekingalpha.com/instablog/8702411-underdawg/2186492-the-many-veils-of-radient-pharmaceuticals-onko-sure-drminus-70

The link below will guide you to the complete analysis to our premisses.

"Radient Restructured By A Planned Reverse Merger"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113309714